Trial Outcomes & Findings for Taekwondo Training and Postmenopausal Women With Stage-2 Hypertension (NCT NCT03544307)

NCT ID: NCT03544307

Last Updated: 2020-11-10

Results Overview

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

20 participants

Primary outcome timeframe

12-weeks

Results posted on

2020-11-10

Participant Flow

Participant milestones

Participant milestones
Measure
Taekwondo Training
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Control
Sedentary control asked not to exercise
Overall Study
STARTED
10
10
Overall Study
COMPLETED
10
10
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Taekwondo Training and Postmenopausal Women With Stage-2 Hypertension

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Control
n=10 Participants
Sedentary control asked not to exercise
Total
n=20 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
>=65 years
10 Participants
n=5 Participants
10 Participants
n=7 Participants
20 Participants
n=5 Participants
Age, Continuous
70 years
STANDARD_DEVIATION 4 • n=5 Participants
70 years
STANDARD_DEVIATION 4 • n=7 Participants
70 years
STANDARD_DEVIATION 4.7 • n=5 Participants
Sex: Female, Male
Female
10 Participants
n=5 Participants
10 Participants
n=7 Participants
20 Participants
n=5 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
10 Participants
n=5 Participants
10 Participants
n=7 Participants
20 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
White
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Region of Enrollment
South Korea
10 participants
n=5 Participants
10 participants
n=7 Participants
20 participants
n=5 Participants
Blood epinephrine levels
43.6 pg/mL
STANDARD_DEVIATION 6.6 • n=5 Participants
43.4 pg/mL
STANDARD_DEVIATION 5.1 • n=7 Participants
43.5 pg/mL
STANDARD_DEVIATION 5.9 • n=5 Participants
Blood norepinephrine levels
268.6 pg/mL
STANDARD_DEVIATION 41.3 • n=5 Participants
243.4 pg/mL
STANDARD_DEVIATION 5.1 • n=7 Participants
256 pg/mL
STANDARD_DEVIATION 23.2 • n=5 Participants
Arterial stiffness
8.41 m/s
STANDARD_DEVIATION 1.0 • n=5 Participants
8.27 m/s
STANDARD_DEVIATION 0.67 • n=7 Participants
8.34 m/s
STANDARD_DEVIATION 0.84 • n=5 Participants
Systolic Blood Pressure
144 mmHg
STANDARD_DEVIATION 2 • n=5 Participants
143 mmHg
STANDARD_DEVIATION 2 • n=7 Participants
144 mmHg
STANDARD_DEVIATION 2 • n=5 Participants
Diastolic Blood Pressure
98 mmHg
STANDARD_DEVIATION 2 • n=5 Participants
99 mmHg
STANDARD_DEVIATION 2 • n=7 Participants
99 mmHg
STANDARD_DEVIATION 2 • n=5 Participants
Hand grip strength
24 kg
STANDARD_DEVIATION 4 • n=5 Participants
25 kg
STANDARD_DEVIATION 4 • n=7 Participants
25 kg
STANDARD_DEVIATION 4 • n=5 Participants
Leg strength
39 kg
STANDARD_DEVIATION 6 • n=5 Participants
38 kg
STANDARD_DEVIATION 7 • n=7 Participants
39 kg
STANDARD_DEVIATION 7 • n=5 Participants

PRIMARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Blood Epinephrine Levels
46.2 pg/mL
Standard Deviation 4.7
39.3 pg/mL
Standard Deviation 7.1

PRIMARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Blood Norepinephrine Levels
330 pg/mL
Standard Deviation 38.2
232.2 pg/mL
Standard Deviation 33.7

SECONDARY outcome

Timeframe: 12-weeks

Pulse Wave Velocity

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Arterial Stiffness
8.48 m/s
Standard Deviation 1.0
7.67 m/s
Standard Deviation 1.0

SECONDARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Systolic Blood Pressure
142 mmHg
Standard Deviation 2
130 mmHg
Standard Deviation 2

SECONDARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Hand Grip Strength
24 kilograms (kg)
Standard Deviation 4
27 kilograms (kg)
Standard Deviation 3

SECONDARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Diastolic Blood Pressure
97 mmHg
Standard Deviation 2
87 mmHg
Standard Deviation 2

SECONDARY outcome

Timeframe: 12-weeks

Outcome measures

Outcome measures
Measure
Control
n=10 Participants
Sedentary control asked not to exercise
Taekwondo Training
n=10 Participants
Taekwondo training was performed 60 minutes/day, 3 days/week for 12-weeks. Exercise intensity was set at 30-40% of heart rate reserve (HRR) and gradually increased to 50-60% over 12 weeks. Taekwondo training: Exercise group
Leg Strength
38 kilograms (kg)
Standard Deviation 8
41 kilograms (kg)
Standard Deviation 7

Adverse Events

Taekwondo Training

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Song-Young Park

The University of Nebraska at Omaha

Phone: 402-554-3774

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place